Clinical Medicine Insights Arthritis and Musculoskeletal Disorders · 2016 · 10 citations · 31 references
MedicineClinical SciencesRadiologyDiagnostic RadiologyPain ManagementRheumatologyAutoimmune Rheumatic DiseasesDisease StagingImaging AssessmentInflammatory ArthritisInflammatory ProcessesRheumatoid ArthritisDisease Activity MeasurementFlare MeasurementInflammatory Arthritis ImagingPharmacological Pain ReliefRheumatoid Arthritis ModelsRheumatoid Arthritis PainRheumatoid Arthritis PharmacotherapyRheumatoid Arthritis Therapy
Objectives The mechanisms that trigger flare in rheumatoid arthritis (RA) are unknown. In murine arthritis models, dysfunctional lymph node (LN) drainage is associated with joint flare. To examine if LN alterations are associated with RA flare, we analyzed the change in LN volume via contrast-enhanced magnetic resonance imaging (CE-MRI) in patients with active joint flare at baseline and 16 weeks after certolizumab pegol (CZP) therapy. We also assessed the changes in popliteal or epitrochlear LN volumes versus the Rheumatoid and Arthritis Outcome Score (RAOS) (knee), or the Michigan Hand Questionnaire (MHQ; wrist/hand), and Disease Activity Score 28 (DAS28), at baseline and 16 weeks. Results Total LN volume in 7 of 10 patients with measurable LN on CE-MRI significantly decreased 16 weeks after CZP therapy (mean decrease 37%; P = 0.0019). Improvement in knee pain measured by the RAOS ( P = 0.03) inversely correlated with a decrease in total popliteal LN volume ( R 2 = 0.94). All patients demonstrated significant improvement in DAS28 (mean decrease 1.48; P = 0.0002). For flare in the hand, significant improvement in activities of daily living (ADL) as measured by the MHQ was observed (left hand mean improvement 20%; P = 0.02; right hand mean improvement 37%; P = 0.03). Conclusion RA patients with the smallest change in LN volume during anti-tumor necrosis factor (anti-TNF) therapy experienced the greatest pain relief in symptomatic knee joints. Moreover, the remarkably linear inverse correlation between LN volume and joint pain observed in this small clinical pilot provides initial evidence to support the concept that dynamic changes in draining LN volume are a biomarker of clinical response to therapy in RA.
31
Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis.
Jeanne Keffer, Lesley Probert, Haris Cazlaris et al. · The EMBO Journal · 1991 · 1.7K citations · Full text
Life Sciences, Genetics, Immunology +14
Stanley Cohen, Paul Emery, Maria Greenwald et al. · Arthritis & Rheumatism · 2006 · 1.6K citations
Josef S Smolen, André Beaulieu, Andrea Rubbert‐Roth et al. · The Lancet · 2008 · 1.4K citations
Medicine, Immunology, Pharmacology +16